A Good Side to Nicotine?

Nicotine holds promise for treating diseases such as attention deficit hyperactivity disorder (ADHD), Parkinson's and Alzheimer's diseases, and schizophrenia. "Nicotine is a very simple molecule, and it affects receptors of many subtypes; therefore, the consequences, behavioral and biologic, are very broad," says Neil Grunberg, director of the Psychoendocrinology and Biochemistry Laboratory at the Uniformed Services University of the Health Sciences. Nicotinic receptors control the release of

Written byHarvey Black
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Nicotine holds promise for treating diseases such as attention deficit hyperactivity disorder (ADHD), Parkinson's and Alzheimer's diseases, and schizophrenia. "Nicotine is a very simple molecule, and it affects receptors of many subtypes; therefore, the consequences, behavioral and biologic, are very broad," says Neil Grunberg, director of the Psychoendocrinology and Biochemistry Laboratory at the Uniformed Services University of the Health Sciences.

Nicotinic receptors control the release of numerous neurotransmitters, including dopamine, acetylcholine, and norepinephrine, "which are important in the acute minute-to-minute running of the brain, your emotions, cognitive aspects of memory," says G. Kenneth Lloyd, a scientific consultant in Poway, Calif. Nicotinic receptors are also involved in controlling nerve growth factors, important for the health of neurons. "The nicotinic receptors seem to be pretty important and pervasive," he comments. There are six different types of nicotinic receptors in humans, says Michael Williams, vice president of neurological and urological diseases at Abbott ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies